New Study: Liver Fibrosis Drugs Market Forecast To 2025

Liver fibrosis is the most common liver condition. It is the imbalance of decomposition and synthesis of the extra cellular matrix (ECM) and collagens caused by necrosis and liver cell inflammation. Cellular components primarily are fibroblastic cells, hepatic stellate cells (HSC), and mononuclear macrophages cells. Extra cellular matrix (ECM) is composed of glycoproteins, collagen, and protein-polysaccharides. Fibrosis is a process when connective tissue starts to proliferate in the portal area.

View Report: https://www.transparencymarketresearch.com/liver-fibrosis-drugs-market.html

In a normal liver, 5.5 mg to 6.5 mg of collagen can be found in every gram of liver tissue. Cirrhotic liver contains over 8.0 mg of collagen in every gram of liver tissue. It can also be higher than 20 mg. Liver fibrosis can be categorized into viral hepatitis fibrosis, parasitic infection fibrosis, alcoholic fibrosis, biliary fibrosis, intoxication fibrosis, cardiogenic fibrosis, and metabolic fibrosis. Immunologically, liver fibrosis can be categorized into passive fibrosis and active fibrosis. Viral hepatitis fibrosis is the most common form of liver fibrosis and is usually caused by chronic hepatitis C, B, and D. According to PubMed and scientific journal research, over 500 million people are affected by hepatitis B and C virus. Infected people develop chronic hepatitis, which leads to fibrosis. Liver fibrosis can cause major complications, including liver failure, portal hypertension, and liver cancer. The risk of liver cancer is greatly increased once fibrosis develops. Liver cancer is among the top ten causes of death globally. High alcohol consumption, fatty liver (steatosis), and insulin resistance increase the risk of liver fibrosis.

The global liver fibrosis drugs market is expanding significantly due to increase in prevalence of the disease. Long term medication also increases the incidence of liver fibrosis. Rise in funding by government and private sector for the treatment of liver fibrosis in terms of reimbursement is projected to drive the market during the forecast period. Low rate of voluntary screening for the disease is a major restraint of the market.

Request a Brochure of the Report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37853

The global liver fibrosis drugs market can be segmented based on drug class, distribution channel, and region. In terms of drug class, the market can be categorized into interferon (IFN) therapy, nucleoside analogue, maloti lipid, and others.

Based on distribution channel, the global liver fibrosis drugs market can be classified into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of revenue, the hospital pharmacies segment is projected to hold a significant share of the liver fibrosis drugs market in 2016.

In terms of region, the global liver fibrosis drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the leading market for liver fibrosis drugs. In terms of revenue, the U.S. holds a major share of the liver fibrosis drugs market in North America. The market in Europe is expanding rapidly due to increase in the patient population in the region, especially in the U.K. and Germany. The market in Asia Pacific and Latin America is projected to expand significantly in the near future. Developing economies such as China and India are anticipated to contribute to the growth of the market in Asia Pacific between 2017 and 2025, due to better health care infrastructure, economic growth, increase in the number of insurance payers, growth of the private health care sector, and increase in awareness among people in these countries.

Request TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=37853

Key players operating in the global liver fibrosis drugs market are Bristol-Myers Squibb Company, Gilead Sciences, Inc., Celgene Corporation, Pfizer, Inc., FibroGen, Inc., Pharmaxis Limited, Dicerna Pharmaceuticals, Inc., LG Life Science Ltd., and Dynavax Technologies Corporation.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact Us

Transparency Market Research

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Be the first to comment

Leave a Reply

Your email address will not be published.


*